MONTVILLE, N.J., and MONTREAL, April 28, 2011 /PRNewswire/ —
Bayer HealthCare Pharmaceuticals and the World Federation of
Hemophilia (WFH) are announcing a three-year extension of Bayer’s
sponsorship agreement with WFH. The agreement calls for Bayer
to serve as sole sponsor of WFH’s International Hemophilia Training
Centre (IHTC) program, in addition to providing support for other
WFH activities, such as its Web site and Congress.
Established in 1969, the IHTC program gives health care
professionals from developing countries training in the diagnosis
and management of hemophilia and related bleeding disorders.
Additionally, Bayer has made a major donation to WFH of
Kogenate® FS, antihemophilic factor (recombinant), a
recombinant factor VIII treatment for hemophilia A, which will be
used for humanitarian aid in countries where persons with
hemophilia A have limited access to care. The donated
Kogenate FS is commercially valued at more than $7 million.
The IHTC program provides clinical, laboratory and paramedical
training in 28 centers worldwide, located in the Americas, Africa
and the Middle East, Asia, Western Pacific and Europe. Most
recently, a new center was designated in Russia in 2010, and plans
are underway to establish a center in Egypt.
“The International Hemophilia Training Centre program is
critical to furthering the treatment of hemophilia and related
disorders around the world,” said Claudia Black, WFH CEO. “We
appreciate our long-standing partnership with Bayer, and commend
the company on its commitment to the hemophilia community to help
us achieve our vision of Treatment for All.”
The centers provide training in all aspects of hemophilia
management, with 35 fellowships awarded each year. Fellowship
candidates are chosen based on their level of commitment and
potential to improve hemophilia treatment in their country, after
the completion of their training period. Fellowsh
‘/>”/>
